Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 12, Issue 4, Pages 463-476Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.12.4.463
Keywords
antisense oligonucleotides; apoptosis; cell cycle; dominant negative mutants; human cancers; inhibitor of apoptosis proteins; ribozymes; smail interfering RNAs; survivin
Categories
Ask authors/readers for more resources
Background: Survivin is a structurally unique member of the inhibitor of protein (IAP) family that acts as a suppressor of apoptosis and plays a central role in cell division. Owing to its massive upregulation in human tumors and its involvement in cancer progression and treatment resistance, survivin is currently undergoing extensive investigation as a novel therapeutic target. Objective: The purpose of this review is to define potential of survivin as a therapeutic target for new anticancer interventions. Methods: The literature dealing with the therapeutic targeting of survivin has been carefully reviewed. Results/conclusion: Several preclinical studies have demonstrated that downregulation of survivin expression or function, accomplished by means of various strategies, reduced growth potential, increased the apoptotic rate and sensitized tumor cells to chemotherapeutic drugs and radiation in different human tumor models. Moreover, the first survivin inhibitors are being currently evaluated in clinical settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available